Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 16/20 | 0.76 |
| ▸ | IKBKB | O14920 | 1/20 | 0.40 |
| ▸ | MET | P08581 | 1/20 | 0.40 |
| ▸ | AXL | P30530 | 1/20 | 0.40 |
| ▸ | MERTK | Q12866 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.39 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.39 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.39 |
| ▸ | PARP16 | Q8N5Y8 | 1/20 | 0.39 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.39 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2482445 | 0.86 | AURKA (1.00) | AURKASMN1; SMN2 | |
| SCHEMBL6524888 | 0.80 | AURKA (0.52) | AURKAIKBKBPARP10 | |
| SCHEMBL2487718 | 0.75 | AURKA (0.65) | AURKA | |
| SCHEMBL17074444 | 0.71 | AURKA (0.80) | AURKAMETAXLMERTK | |
| SCHEMBL2483272 | 0.71 | AURKA (1.00) | AURKAMETAXLMERTK | |
| SCHEMBL2484531 | 0.69 | AURKA (0.55) | AURKA | |
| SCHEMBL15541791 | 0.65 | PARP10 (0.43) | IKBKBMETAXLMERTKALDH1A1 | |
| SCHEMBL6522251 | 0.65 | AURKA (0.52) | AURKAMET | |
| SCHEMBL6521890 | 0.65 | AURKA (0.63) | AURKA | |
| SCHEMBL6517924 | 0.64 | AURKA (0.50) | AURKAMETAXLMERTKPARP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2367821-B1 | C-RING MODIFIED TRICYCLIC BENZONAPHTHIRIDINONE PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK PATENT GMBH (DE) | 2015-09-16 | — | — | EP | claimed |
| US-20110312951-A1 | C-Ring Modified Tricyclic Benzonaphthiridinone Protein Kinase Inhibitors and Use Thereof | MERCK PATENT GMBH (DE) | 2011-12-22 | — | — | US | claimed |
| WO-2010077530-A1 | C-RING MODIFIED TRICYCLIC BENZONAPHTHIRIDINONE PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK PATENT GMBH (DE) | 2010-07-08 | — | — | WO | claimed |
| US-9938268-B2 | C-ring modified tricyclic benzonaphthiridinone protein kinase inhibitors and use thereof | MERCK PATENT GMBH (DE) | 2018-04-10 | — | — | US | disclosed |
| EP-2367821-B1 | C-RING MODIFIED TRICYCLIC BENZONAPHTHIRIDINONE PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK PATENT GMBH (DE) | 2015-09-16 | — | — | EP | disclosed |
| US-20110312951-A1 | C-Ring Modified Tricyclic Benzonaphthiridinone Protein Kinase Inhibitors and Use Thereof | MERCK PATENT GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312951-A1 | C-Ring Modified Tricyclic Benzonaphthiridinone Protein Kinase Inhibitors and Use Thereof | PRKCB, PNCK, PACSIN2 | AURKA 562/4885IKBKB 191/4885MET 2416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.